Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3882347 CYP3A4 Induction Potential Study
NCT05760261Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GSK3882347 in urinary tract infection (UTI), sponsored by GSK. Primary endpoints: Area under the curve from time zero to 24 hours for plasma concentration of Midazolam (Period 1), Area under the curve from time zero to 24 hours for plasma concentration of 1-hydroxy-Midazolam (Period 1) and 6 more. Started Apr 2023; status: completed.
02
Drugs
GSK3882347
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT05760261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760261.